NextCure (NXTC) Q1 2026 earnings summary

Executive summary

• Achieved FDA Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, with Phase 1 dose optimization initiated and data to be presented at ASCO 2026; expanded trial sites planned in North America and Europe.

• Lead programs SIM0505 and LNCB74 are in clinical development, targeting patients unresponsive to current therapies.

• LNCB74 Phase 1 trial ongoing, with protocol amendments for higher dose escalation and expanded enrollment; proof-of-concept data delayed to H2 2026.

• No product revenue to date; operations funded by equity offerings, collaborations, and a 50-50 global co-development with LigaChem for LNCB74.

Financial highlights

• Net loss for Q1 2026 was $9.8 million, compared to $11.0 million in Q1 2025.

• Research and development expenses decreased to $6.8 million from $7.9 million year-over-year.

• General and administrative expenses fell to $3.3 million from $3.7 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $29.7 million as of March 31, 2026, down from $41.8 million at year-end 2025.

• Current financial resources expected to fund operations into the first half of 2027.

Outlook and guidance

• Substantial doubt exists regarding ability to continue as a going concern for one year without additional funding.

• Additional capital required to advance clinical programs beyond H1 2027; cost-cutting measures may be implemented if funding is insufficient.

• SIM0505 Phase 1 data to be presented at ASCO 2026, with further trial site expansion planned.

• LNCB74 trial update anticipated in H2 2026.

• Proof-of-concept for SIM0505 expected within current cash runway.